Status: Recruiting
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.
Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 12-45Biological sex: AllType: InterventionalSponsor: Arkansas Children's Hospital Research InstituteUpdated: Jun 4, 2026Locations: 4
Eligibility criteria
History of stroke and/or vasculopathy, including evidence of asymptomatic cerebr... [+6]
Presence of an HLA-matched sibling who is willing and able to donate bone marrow... [+13]